Related Experiment Videos
Minimally invasive direct coronary artery bypass for redo patients
K Miyaji1, R K Wolf, J B Flege
1Department of Cardiac Surgery, The Christ and Jewish Hospital, University of Cincinnati, Ohio, USA.
Insights
Minimally invasive direct coronary artery bypass (MIDCAB) is a safe option for redo heart surgery patients. Results for redo MIDCAB procedures are comparable to first-time operations, showing similar outcomes in mortality, morbidity, and hospital stay.
Area of Science:
- Cardiovascular Surgery
- Minimally Invasive Cardiac Procedures
Background:
- Minimally invasive direct coronary artery bypass (MIDCAB) is recommended for high-risk patients due to lower trauma compared to conventional coronary artery bypass grafting.
- MIDCAB may be advantageous for redo patients with existing grafts and adhesions, minimizing graft manipulation and dissection.
Purpose of the Study:
- To evaluate the surgical outcomes of redo MIDCAB procedures.
- To compare the results of redo MIDCAB operations with first-time MIDCAB operations.
Main Methods:
- Review of 25 redo MIDCAB cases performed since November 1995.
- Analysis of surgical results including mortality, morbidity, hospital stay, operation time, and inotropic support.
- Comparison between redo and first-time MIDCAB patient groups.
Main Results:
- Redo MIDCAB had one operative death (4%) due to intestinal infarction.
- Mean hospital stay was 4.3 days, with 12% requiring inotropic support.
- No significant differences were found between redo and first-time MIDCAB in key outcome measures.
Conclusions:
- The MIDCAB procedure demonstrates comparable safety and efficacy in redo patients versus primary cases.
- MIDCAB is a viable option for patients requiring repeat coronary artery bypass surgery.
Background:
The minimally invasive direct coronary artery bypass (MIDCAB) procedure, using a small anterolateral thoracotomy without cardiopulmonary bypass, has been recommended for high-risk patients because it is less traumatic than conventional coronary artery bypass grafting. For redo patients who have patent grafts and pericardial adhesions, the MIDCAB may be preferable to the conventional operation because manipulation of the graft and dissection of adhesions may be minimized.
Methods:
Since November 1995, 120 patients underwent the MIDCAB procedure in our institution. Among these patients, there were 25 redo cases (20.8%). We reviewed these redo cases and studied their surgical results (mortality, morbidity, hospital stay, operation time, and postoperative inotropic support). To clarify the usefulness of this procedure, we compared the results of redo operations with those of the first-time operations.
Results:
For redo MIDCAB, there was one operative death (4%) because of intestinal infarction. The mean hospital stay was 4.3 days and the number of patients who needed postoperative positive inotropic agents was 3 (12%). There was no significant differences between redo and first-time operation patients in mortality, morbidity, hospital stay, operation time, and postoperative inotropic support.
Conclusions:
Results of the MIDCAB procedure for redo patients were comparable to those for primary MIDCAB operations.